Millipore Sigma Vibrant Logo

AB755P Anti-Rat Collagen Type I Antibody

View Products on Sigmaaldrich.com
AB755P
100 µg  
Prix en cours de récupération
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
Maximum Quantity is
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitée
Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      Offres spéciales

       

      Contacter le Service Clients

      Aperçu

      Replacement Information

      Offres spéciales

      Tableau de caractéristiques principal

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      RELISA, ICC, IH(P), RIARbAffinity PurifiedPolyclonal Antibody
      Description
      Catalogue NumberAB755P
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Rat Collagen Type I Antibody
      OverviewCollagen Type I extracted and purified from rat skin. Antibody shows less than 0.1% reactivity with human, mouse, chicken Collagen Type I, rat Collagen Types II, III and V and rat Elastin.
      Background InformationCollagens are highly conserved throughout evolution and are characterised by an uninterrupted "Glycine X Y" triplet repeat that is a necessary part of the triple helical structure. Type I collagen (95 kDa) is found in bone, cornea, skin and tendon. Mutations in the encoding gene are associated with osteogenesis imperfecta, Ehlers Danlos syndrome, and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for Platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the growth factor.
      References
      Product Information
      FormatAffinity Purified
      Control
      • Rat hepatic stellate cell lysate
      PresentationThe purified antibody is supplied in a buffer containing a mixture of 0.1M Citrate, 0.1M potassium phosphate, at a pH of 7.2-7.4 and 10µl/ml of antibiotics and antimycotics
      Quality LevelMQ100
      Applications
      ApplicationAnti-Rat Collagen Type I Antibody is an antibody against Collagen Type I for use in ELISA, IC, IH(P), RIA.
      Key Applications
      • ELISA
      • Immunocytochemistry
      • Immunohistochemistry (Paraffin)
      • Radioimmunoassay
      Applications Not Recommended
      • Western Blotting
      Application NotesELISA:
      A 1:200 dilution of a previous lot was used in ELISA.

      RIA:
      A previous lot of this antibody was used in RIA.

      Immunocytochemistry:
      A 1:40-1:80 dilution of a previous lot was used for immunofluorescent staining of frozen rat skin and liver tissues.
      Can also be used for acetone-fixed cells.

      Immunohistochemistry:
      1:40-1:80 dilution for immunofluorescent staining of frozen rat skin and liver tissues. The antibody is also reactive on paraffin embedded rat tissues (skin, liver) at a tdilution of 1:500 using an ABC detection system.

      Not recommended for Western blots.
      Optimal working dilutions must be determined by the end user.
      Biological Information
      ImmunogenCollagen Type I extracted and purified from rat skin.
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostRabbit
      SpecificityRecognizes Rat Collagen Type I
      IsotypeIgG
      Species Reactivity
      • Rat
      Species Reactivity NoteThe antibody shows less than 0.1% reactivity with human, mouse, chicken Collagen Type I, rat Collagen Types II, III and V and rat Elastin.
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos syndrome Classical type, Caffey Disease and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the growth factor. Two transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene. [provided by R. Dalgleish]
      Gene Symbol
      • COL1A1
      • OI4
      Purification MethodImmunoAffinity Purified
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P02452 # Type I collagen is a member of group I collagen (fibrillar forming collagen).
      SIZE: 1464 amino acids; 138911 Da
      SUBUNIT: Trimers of one alpha 2(I) and two alpha 1(I) chains. Interacts with MRC2 (By similarity).
      SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular matrix (By similarity).
      TISSUE SPECIFICITY: Forms the fibrils of tendon, ligaments and bones. In bones the fibrils are mineralized with calcium hydroxyapatite.
      PTM: Proline residues at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains. & O-linked glycan consists of a Glc-Gal disaccharide bound to the oxygen atom of a post-translationally added hydroxyl group.
      DISEASE: SwissProt: P02452 # Defects in COL1A1 are the cause of Caffey disease [MIM:114000]; also known as infantile cortical hyperostosis. Caffey disease is characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones may also appear inflamed, with painful swelling and systemic fever often accompanying the illness. The bone changes usually begin before 5 months of age and resolve before 2 years of age. & Defects in COL1A1 are a cause of Ehlers-Danlos syndrome type I (EDS-I) [MIM:130000]; also known as Ehlers-Danlos syndrome gravis. Ehlers-Danlos syndrome is a genetically and phenotypically heterogeneous connective-tissue disorder characterized by loose- jointedness and fragile, velvety, stretchable, bruisable skin that heals with peculiar 'cigarette-paper' scars. EDS-I is an autosomal dominant trait. & Defects in COL1A1 are a cause of autosomal dominant Ehlers-Danlos syndrome type VII (EDS-VII) [MIM:130060]; which includes also Ehlers-Danlos syndrome type VII-A1. EDS-VII is characterized by arthrochalasis multiplex congenita, skin hyperextensibility and bruisability. & Defects in COL1A1 are a cause of osteogenesis imperfecta type I (OI-I) [MIM:166200]. OI-I is a dominantly inherited serious newborn disease characterized by bone fragility, normal stature, little or no deformity, blue sclerae and hearing loss in 50% of families. Dentinogenesis imperfecta is rare and may distinguish a subset of OI type I (formation of dentine). & Defects in COL1A1 are a cause of osteogenesis imperfecta type II (OI-II) [MIM:166210]; also known as osteogenesis imperfecta congenita. OI-II is lethal in the perinatal period and is charaterized by calvarial mineralization, beaded ribs, compressed femurs, marked long bone deformity and platyspondyly (congenital flattening of the vertebral bodies). & Defects in COL1A1 are a cause of osteogenesis imperfecta type III (OI-III) [MIM:259420]; also called progressively deforming osteogenesis imperfecta with normal sclerae. OI-III is characterized by progressively deforming bones, usually with moderate deformity at birth, sclerae is variable in color, dentinogenesis imperfecta and hearing loss are common. The stature is very short. & Defects in COL1A1 are a cause of osteogenesis imperfecta type IV (OI-IV) [MIM:166220]. OI-IV is charaterized by normal sclerae, moderate to mild deformity and variable short stature. Dentinogenesis imperfecta is common and hearing loss occurs in some patients. & Genetic variations in COL1A1 are associated with susceptibility to involutional osteoporosis [MIM:166710]; also known as senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mineral density, disrutption of bone microarchitecture, and the alteration of the amount and variety of non-collagenous proteins in bone. Osteoporotic bones are more at risk of fracture. & A chromosomal aberration involving COL1A1 is a cause of dermatofibrosarcoma protuberans (DFSP) [MIM:607907]. Translocation t(17;22)(q22;q13) with PDGF. DFSP is an uncommon, locally aggressive, but rarely metastasizing tumor of the deep dermis and subcutaneous tissue. It typically occurs during early or middle adult life and is most frequently located on the trunk and proximal extremities.
      SIMILARITY: SwissProt: P02452 ## Belongs to the fibrillar collagen family. & Contains 1 VWFC domain
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceImmunohistochemistry(paraffin):
      Collagen Type I (cat. # AB755P) staining pattern/morphology in rat skin. Tissue is pre-treated with Citrate pH 6.0, antigen retrieval. This lot of antibody is diluted to 1:1000, using IHC-Select® reagents used with HRP-DAB. Immunoreactivity is seen fiber-staining on paraffin section. Note that the staining pattern is as expected.

      IHC-Paraffin Staining With Epitope Retrieval: Rat Skin
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at -20ºC from date of receipt.
      Packaging Information
      Material Size100 µg
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      AB755P 04053252339028

      Documentation

      Anti-Rat Collagen Type I Antibody FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Anti-Rat Collagen Type I Antibody Certificats d'analyse

      TitreNuméro de lot
      Anti-Rat Collagen Type I - 2446738 2446738
      Anti-Rat Collagen Type I - 1986132 1986132
      Anti-Rat Collagen Type I - 2208759 2208759
      Anti-Rat Collagen Type I - 3243499 3243499
      Anti-Rat Collagen Type I - 3510285 3510285
      Anti-Rat Collagen Type I - 3787682 3787682
      Anti-Rat Collagen Type I - 3905496 3905496
      Anti-Rat Collagen Type I - 4040829 4040829
      Anti-Rat Collagen Type I - 4157263 4157263
      Anti-Rat Collagen Type I - JC1618207 JC1618207

      Références bibliographiques

      Aperçu de la référence bibliographiqueApplicationEspèceNº PubMed
      An Autologous Muscle Tissue Expansion Approach for the Treatment of Volumetric Muscle Loss.
      Ward, CL; Ji, L; Corona, BT
      BioResearch open access  4  198-208  2015

      Afficher le résumé
      26309796 26309796
      Heterogeneity in arterial remodeling among sublines of spontaneously hypertensive rats.
      Bakker, EN; Groma, G; Spijkers, LJ; de Vos, J; van Weert, A; van Veen, H; Everts, V; Arribas, SM; VanBavel, E
      PloS one  9  e107998  2014

      Afficher le résumé
      ImmunohistochemistryRat25251068 25251068
      Autologous minced muscle grafts: a tissue engineering therapy for the volumetric loss of skeletal muscle.
      Corona, BT; Garg, K; Ward, CL; McDaniel, JS; Walters, TJ; Rathbone, CR
      American journal of physiology. Cell physiology  305  C761-75  2013

      Afficher le résumé
      23885064 23885064
      Cessation of epithelial Bmp signaling switches the differentiation of crown epithelia to the root lineage in a β-catenin-dependent manner.
      Yang, Z; Hai, B; Qin, L; Ti, X; Shangguan, L; Zhao, Y; Wiggins, L; Liu, Y; Feng, JQ; Chang, JY; Wang, F; Liu, F
      Molecular and cellular biology  33  4732-44  2013

      Afficher le résumé
      24081330 24081330
      Intra-articular changes precede extra-articular changes in the biceps tendon after rotator cuff tears in a rat model.
      Cathryn D Peltz,Jason E Hsu,Miltiadis H Zgonis,Nicholas A Trasolini,David L Glaser,Louis J Soslowsky
      Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons ... [et al.]  21  2011

      Afficher le résumé
      21816629 21816629
      Induction of osteogenic differentiation of adipose derived stem cells by microstructured nitinol actuator-mediated mechanical stress.
      Strauß, S; Dudziak, S; Hagemann, R; Barcikowski, S; Fliess, M; Israelowitz, M; Kracht, D; Kuhbier, JW; Radtke, C; Reimers, K; Vogt, PM
      PloS one  7  e51264  2011

      Afficher le résumé
      ImmunocytochemistryHuman23236461 23236461
      Structural and functional analysis of intra-articular interzone tissue in axolotl salamanders.
      Cosden-Decker, RS; Bickett, MM; Lattermann, C; MacLeod, JN
      Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society  20  1347-56  2011

      Afficher le résumé
      Immunohistochemistry22800772 22800772
      A standardized rat model of volumetric muscle loss injury for the development of tissue engineering therapies.
      Wu, X; Corona, BT; Chen, X; Walters, TJ
      BioResearch open access  1  280-90  2011

      Afficher le résumé
      23515319 23515319
      Cell-derived matrix enhances osteogenic properties of hydroxyapatite.
      Gregory Tour,Mikael Wendel,Ion Tcacencu
      Tissue engineering. Part A  17  2010

      Afficher le résumé
      20695777 20695777
      Matrix metalloproteinase-8 overexpression prevents proper tissue repair.
      Patricia L Danielsen,Anders V Holst,Henrik R Maltesen,Maria R Bassi,Peter J Holst,Katja M Heinemeier,Jørgen Olsen,Carl C Danielsen,Steen S Poulsen,Lars N Jorgensen,Magnus S Agren
      Surgery  150  2010

      Afficher le résumé
      21875735 21875735

      Produits & Applications associés

      Related Products

      Familles de produits

      Catégories

      Life Science Research > Antibodies and Assays > Primary Antibodies